Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 |Industry: Pharmaceuticals
|Expensive Performer
Durability score
40 /100
Valuation score
27.8 /100
Momentum score
46.6 /100
Market Capitalizati...
35,051.5 Cr.
AVG Broker Target
807.4
PE TTM Price to Ear...
13.8
Aurobindo Pharma Ltd.    
20 Aug 2019
598.25
1.26%
Way2Wealth
US Business US revenue grew by 42% YoY and to `26,884 mn. On a constant currency basis, US revenue increased by 37% year-on-year basis to $387 million led by new product launches and improvement in volumes of existing products. Revenue of Aurobindo Pharma USA, the company marketing oral products in the US increased by 32% YoY, while Revenue of AuroMedics (injectable business) witnessed a growth of 86% year-on-year to $67 million. During the quarter, Aurobindo witnessed the full impact of consolidation Spectrum Pharmaceuticals. 40 more new products are expected to be launched in the next 9 months. Price erosion in the base business was below 5% for the quarter. Approval...
Aurobindo Pharma Ltd. is trading above it's 50 day SMA of 589.22
Aurobindo Pharma Ltd.    
19 Aug 2019
598.25
1.26%
Promoters pledge increased to 3.82% of holdings in Jun 2019 qtr.
Aurobindo Pharma Ltd.    
12 Aug 2019
598.25
1.26%
buy
Sharekhan
Aurobindo Pharma Limited (Aurobindo) reported a strong set of numbers in Q1FY2020. Sales rose by a strong 28.1% y-o-y to Rs 5,444.6 crore (6% above our estimates), driven by strong growth in formulation business across geographies. Operating profit increased by 47.1% y-o-y to Rs. 1,146.4 crore (15.3% above our estimates). Gross margin improved by 270 bps y-o-y to 57.8%. OPM improved by 272 bps y-o-y to 21.1% (168 bps above our estimate of 19.4%). Adjusted PAT grew by 22.1% y-o-y to Rs. 638.9 crore (7.9% above our estimate)....
Number of FIIs/FPIs holding stock fell by 20 to 627 in Jun 2019 qtr.
Aurobindo Pharma Ltd.    
10 Aug 2019
598.25
1.26%
Emkay
Q1FY20 EBITDA beat estimate by 12%, led by better gross margins (+260bps qoq; strong US, weak API) and lower R&D; spends (4.5% vs. ~5% guided incl. the Sandoz acquisition). The other positives are strong US sales and a reduction in net debt by US$130mn qoq. Despite no meaningful launches, the US business (US$387mn, +10% qoq) continued to remain strong, led by Injectables (US$67mn, flat qoq despite gErtapenem competition), addition of Spectrum portfolio (~US$25mn) and stable base business (<5% price erosion). The Sandoz deal is expected to close in the near future and should be a key near-term trigger (can add ~15% to our estimates). ARBP has shown exemplary execution in the US...
Aurobindo Pharma Ltd. is trading below it's 100 day SMA of 661.54
Aurobindo Pharma Ltd.    
09 Aug 2019
598.25
1.26%
Nirmal Bang Institutional
Aurobindo Pharma's (APL) 1QFY20 revenue at Rs54,446mn is up 3% QoQ and 2.2%/0.6% above/below our/consensus estimates, respectively. The Formulations business grew by 34.6% YoY and 7.7% QoQ, led by the full quarter impact of consolidation of sales of Spectrum Pharma portfolio and growth in Sartan portfolio sales in the US. During the quarter, 15 new products were launched in the US, which includes 4 injectables. The new launches during the quarter should help APL to more than offset any potential erosion in its key portfolio asset Ertapenem, which witnessed entry of a new player in the previous quarter. The launch pipeline over the next 9 months also remains strong with 40 incremental launches expected. Remediation efforts around...
Way2Wealth released a Results Update report for Aurobindo Pharma Ltd. on 20 Aug, 2019.
Aurobindo Pharma Ltd.    
08 Aug 2019
598.25
1.26%
BOB Capital Markets Ltd.
Q1FY20 revenue/EBITDA beat estimates by 8%/10% spurred by strong US sales at US$ 384mn and 260bps gross margin expansion YoY and QoQ.
Aurobindo Pharma Ltd. is trading above it's 50 day SMA of 589.22
Aurobindo Pharma Ltd.    
08 Aug 2019
598.25
1.26%
Prabhudas Lilladhar
The Q1FY20 sales, adj. EBITDA and PAT beat our estimates by 7%, 9% and Change in Estimates | Target | Reco 2% respectively. While the injectable business was in line with guidance, its flat growth with sales of US$67m in US injectable, despite seasonal...
Promoters pledge increased to 3.82% of holdings in Jun 2019 qtr.
Aurobindo Pharma Ltd.    
08 Aug 2019
598.25
1.26%
ICICI Securities Limited
US key growth driver; acquisitions to strengthen US basket After filing ANDA in the US in 2003, the company has come a long way as current ANDA filings are at 551. US revenues have grown from ~US$100 million in 2009 crossing $1 billion sales as on 2017. In rupee terms, US sales have grown at 17% CAGR to | 9031 crore in FY15-19. US formulations now constitute 46% of total turnover, up from 30% in FY13. Post acquisition of Sandoz' US dermatology and oral solid businesses, Aurobindo will become the second largest generic player in the US by number of prescriptions. Due...
Aurobindo Pharma Ltd. is trading below it's 100 day SMA of 661.54
Aurobindo Pharma Ltd.    
03 Jul 2019
598.25
1.26%
Motilal Oswal
The WL highlighted that the company has initiated recalls/additional process controls and testing of all manufactured batches of certain API, post the mention by regulatory agencies. There has been failure to ensure that equipment surface in contact with the API does not alter it beyond the established specification. Though the company has engaged a consultant to evaluate operations, the WL highlighted that the firms management will be responsible for fully resolving all deficiencies to ensure CGMP compliance. The WL also indicated that the USFDA has cited similar CGMP observations at other sites Unit I and Unit IX. the USFDA would require comprehensive measures to ensure adequate quality oversight of operations/equipment that could affect the drug quality, including any revised qualification and evaluation procedures. The USFDA would also require an update on the CAPA plans already initiated by ARBP, in addition to a thorough review of all API batches made at ARBP sites, in terms of impurities above reported thresholds.
default
Aurobindo Pharma Ltd. is trading above it's 50 day SMA of 589.22
Aurobindo Pharma Ltd.    
28 Jun 2019
598.25
1.26%
buy
Sharekhan
A Warning Letter has been issued to Aurobindo Pharma Limited (Aurobindo) for its Unit-XI, an Active Pharmaceutical Ingredient (API) unit in Srikakulam, one of the three plants that received Official Action Indicated (OAI) status in May 2019. The letter mainly pertains to the ongoing issues regarding impurities in Sartan's. The company proposes to enter into dialogue with the US FDA over the next 1520 days to decide a future course of action. From Unit XI, the company...
Number of FIIs/FPIs holding stock fell by 20 to 627 in Jun 2019 qtr.